The R231Q mutation variant of DOT1L selectively activates the MAPK/ERK signaling pathway in lung cancer cells by enriching H3K79me2 on the RAF1 promoter and epigenetically regulating the expression of downstream targets. The gene discussed is DOT1L; the disease is lung cancer.